# Galectin-3 and engineered variants for clustering glycolipids and glycoproteinson membrane surfaces

> **NIH NIH R15** · UNIVERSITY OF COLORADO · 2023 · $429,928

## Abstract

PROJECT SUMMARY / ABSTRACT
Molecule clustering at the cell surface is critical for controlling cell signaling and behavior, and ~70% of drugs
bind membrane protein targets. Currently, most drugs are designed around inhibiting a specific transmembrane
receptor, but there is untapped potential to target molecule clustering to control cell behavior. Galectin proteins
regulate molecule clustering because they bind and assemble a variety of β-galactoside-decorated lipids and
proteins. For example, galectin-3 (Gal-3) is overexpressed up to 30-fold in metastasizing cancer cells,
suggesting a role in cell adhesion. Gal-3’s transmembrane binding partner, MUC1, is aberrantly expressed on
~75% of human solid tumor cancers. Gal-3 also mediates neuronal cell growth through interactions with the
glycolipid ganglioside GM1. Wild type (WT) galectin proteins are organized into three unique molecular
architectures which are hypothesized to direct molecule clustering: homodimers, tandem-repeat dimers with
flexible linkers, and a chimeric-type that promotes oligomerization. WT Gal-3 is a chimeric-type protein. We
hypothesize that Gal-3 directs MUC1 and GM1 clustering at the membrane surface and that cluster organization
can be directed by engineered changes in Gal-3 molecular architecture (homodimer, tandem-repeat, or chimera).
If the proposed research is successful, this will lay the foundation for controlling cell behavior through surface-
mediated clustering of glycan molecules. This is broadly applicable to many cellular functions including
apoptosis, cell adhesion, and neuronal development. We propose two goals: (1) determine the structure of
Gal-3 binding MUC1 and GM1 on a membrane surface and (2) characterize engineered Gal-3 variants to
determine how galectin molecular architecture directs glycan clustering patterns. The innovation is to use liquid
surface synchrotron X-ray scattering and engineered galectin variants. Aim 1 will characterize WT Gal-3 binding
to glycolipid GM1 and glycoprotein MUC1 on a model membrane. This will be performed using synchrotron X-
ray scattering and fluorescence microcopy. X-ray reflectivity will be used to determine the electron density
profile of the membrane, and grazing incidence X-ray diffraction will be used to characterize semi-ordered
species such as lipid domains or Gal-3 assemblies. Fluorescence microscopy will be used to characterize lipid
phase separation and glycoprotein/lipid organization using a phase-sensitive dye and BODIPY-labeled glycans.
Aim 2 will determine how engineered Gal-3 variants cluster glycoprotein/lipid substrates. The engineered
variants include homodimer and tandem-repeat forms of Gal-3, which are expected to cause different clustering
patterns. This will be accomplished with the same methods as Aim 1. Aim 3 supports goal 1 by using
molecular dynamics simulations to model the atomic structure of Gal-3 binding GM1 in a membrane. These
simulations will determine the molecule cluster size, membrane...

## Key facts

- **NIH application ID:** 10652941
- **Project number:** 1R15GM150123-01
- **Recipient organization:** UNIVERSITY OF COLORADO
- **Principal Investigator:** Crystal Marie Vander Zanden
- **Activity code:** R15 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $429,928
- **Award type:** 1
- **Project period:** 2023-07-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10652941

## Citation

> US National Institutes of Health, RePORTER application 10652941, Galectin-3 and engineered variants for clustering glycolipids and glycoproteinson membrane surfaces (1R15GM150123-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10652941. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*